OHSU

IRB #

IRB00010426

Title

Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors

Principal Investigator

Matthew Taylor

Study Purpose

To learn if MEK162 (the study drug) is safe and has beneficial effects in people who have different types of cancer with pre-identified RAS/RAF/MEK mutations.

Medical Condition(s)

Select solid tumors and hematologic malignancies with RAF/RAS/MEK tumor activations

Eligibility Criteria

1. Male or female of at least 18 years of age.
2. Diagnosis of select solid tumor (except pancreatic, biliary, colorectal, low grade serous ovarian, and melanoma) or hematologic malignancy.
3. Pre-identified RAF, RAS, NF1, or MEK mutation.
4. Received at least one prior treatment for recurrent, metaastatic, and/or locally advanced disease.
5. Other criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression or development of unacceptable side effects

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Novartis

Recruitment End

08/31/2015

Compensation Provided

No


Go Back